GlycoMAb®
GlycoMAb® is based on the Company’s pioneering demonstration that antibody glycosylation can be engineered in a fashion which dramatically and specifically increases antibody-dependent cellular cytotoxicity (ADCC). This immune effector mechanism is crucial for the in vivo target-cell killing activity of antibodies.
GlycoMAb® has the potential to address major challenges in the antibody field:
- Expanding the therapeutic window of a given antibody and providing treatment for patients which do not respond to current treatment options
- Reducing product attrition and avoiding costly failures, especially in late-stage clinical trials
- Enabling life cycle management by producing second generation versions of innovator’s own product
- Generating economically more attractive products (i.e., lower use of manufacturing capacity, reduced investment costs for manufacturing, reduced doses and frequency of injection, higher patient benefit and convenience)
- Providing a unique competitive advantage for unconjugated antibodies in a highly competitive market
 |
All rights reserved. © GLYCART biotechnology AG 2008 |